UBE2S and hepatocellular carcinoma: In addition, in liver orthotopic xenograft tumor models, the results also indicated that tumors in the UBE2S‐shRNA group treated with sorafenib were smaller than those in their negative control group treated with sorafenib, suggesting that knockdown of UBE2S made HCC cells more sensitive to sorafenib in vivo (Figure 9F,G).